A Phase III Study of GS101 Injection to Dupixent®

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase III Study of GS101 Injection to Dupixent®	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder	Not yet recruiting	Phase 3	2026-02-04		NCT07386743

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Jiangsu Genscend Biopharmaceutical Co., Ltd	2

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
The First Hospital of China Medical University	Shenyang	China	43

Clinical trials